Bruker introduces innovative Sierra SPR-32 system at European SLAS 2018 meeting

At the European SLAS 2018 meeting, Bruker announced the launch of its new SierraTM SPR-32 system with even higher sensitivity and new instrument control software to enable highest SPR throughput with outstanding sensitivity.

Credit: Bruker Corporation

Powered by its new touch-compatible R3 software, the Sierra SPR-32 has innovative new features like 'Frame Inject' and allowing for turn-key sample processing protocols and customized workflows created together with pharmaceutical customers. The faster data analysis and highly intuitive user interface combine to deliver an industry-leading SPR throughput of 10,000 control-substracted binding measurements. Combining flexible 8-needle sample delivery with a 32-sensor detection array laid out in 8 detection flow cells, enables 4 sensors per flow cell, an important advantage for controlled, high-throughput SPR methods. The patented Hydrodynamic Isolation technology enables 'Any Sample, Any Sensor, Any Time', making it the preferred platform for screening, kinetics, thermodynamics and epitope mapping for pharmaceutical applications.

Christopher Whalen, Bruker Director of Global SPR Sales, said:

The new R3 software with the proprietary non-linear detection algorithm and new data processing engine, makes the Sierra SPR-32 even faster and even more sensitive. Our four-sensor per channel design provides maximum control analysis flexibility, enabling good throughput for even the most complex analyses. Samples can be simultaneously assayed on the active sensor and with up to three controls. In many SPR applications the early analysis of non-specific binding to matrix proteins such as HSA or BSA can be critical. The additional inline control not only halves the number of assay cycles required vs. two sensor flow cells, but it can also improve data quality by eliminating potential variations between multiple sample preparations."

Dr. Meike Hamester, the Bruker Daltonics Director - Small Molecule Pharma Business, commented:

The complementary nature of label-free detection technologies represented by the new Sierra SPR-32, and Bruker's NMR and MALDI PharmaPulseTM mass spectrometry solutions for drug discovery can help in the design of efficacious and safer drugs at lower cost. Improving the hit-to-lead identification speed helps, but improving the understanding of the relationship of structure to binding kinetics using liquid phase, label-free techniques, will go a long way in taking new chemical entities to clinical trials faster."

Source: https://www.bruker.com/news/slas/bruker-launches-new-sierratm-spr-32-high-performance-surface-plasmon-resonance-system.html

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Bruker Life Sciences Mass Spectrometry. (2018, June 29). Bruker introduces innovative Sierra SPR-32 system at European SLAS 2018 meeting. News-Medical. Retrieved on October 11, 2024 from https://www.news-medical.net/news/20180629/Bruker-introduces-innovative-Sierra-SPR-32-system-at-European-SLAS-2018-meeting.aspx.

  • MLA

    Bruker Life Sciences Mass Spectrometry. "Bruker introduces innovative Sierra SPR-32 system at European SLAS 2018 meeting". News-Medical. 11 October 2024. <https://www.news-medical.net/news/20180629/Bruker-introduces-innovative-Sierra-SPR-32-system-at-European-SLAS-2018-meeting.aspx>.

  • Chicago

    Bruker Life Sciences Mass Spectrometry. "Bruker introduces innovative Sierra SPR-32 system at European SLAS 2018 meeting". News-Medical. https://www.news-medical.net/news/20180629/Bruker-introduces-innovative-Sierra-SPR-32-system-at-European-SLAS-2018-meeting.aspx. (accessed October 11, 2024).

  • Harvard

    Bruker Life Sciences Mass Spectrometry. 2018. Bruker introduces innovative Sierra SPR-32 system at European SLAS 2018 meeting. News-Medical, viewed 11 October 2024, https://www.news-medical.net/news/20180629/Bruker-introduces-innovative-Sierra-SPR-32-system-at-European-SLAS-2018-meeting.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Nanoparticles, mass spectrometry, and more – exploring new avenues for proteomics analysis